CDT Equity Inc.

CDT Healthcare Biotechnology

In the quarter to June 2026, EPS grew 98.0% and free cash flow grew 78.9%, each against the same quarter a year earlier.

0.24 0.03 +14.29%
Market cap
$240.0K
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '17
Current Ratio
0.34 0.25 3.18 0.15 0.54 —
Net Debt/EBITDA
0.05 0.04 0.88 (0.47) 11.05 —
Debt/Equity
0.00 0.00 0.00 (0.18) 0.00 —
ROE
561.83% 491.09% 10.15% 97.08% 0.00% —
ROA
(796.99%) (311.85%) (14.80%) (4,481.43%) (4.13%) —
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% —
Return on Tangible Assets
479.98% 222.92% (13.61%) 138.47% 4.98% —
Free Cash Flow per Share
(163,630.00) 0.00 (11.53) (0.06) 0.00 —
Book value per Share
(71,700.00) 0.00 (0.68) (0.27) 0.01 —
Free Cash Flow
(16.36) (9.73) (7.72) (2.27) (0.01) —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026